Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Stock Information for Outlook Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Outlook Therapeutics Inc.

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA(TM) (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA(TM) (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
Outlook Therapeutics® Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.